MDSCs Cancer Research Results

MDSCs, Myeloid-derived suppressor cells: Click to Expand ⟱
Source:
Type:
Myeloid-derived suppressor cells (MDSCs) are a type of immune cell that plays a significant role in cancer progression and immune evasion. They are a heterogeneous group of cells that are characterized by their ability to suppress the immune response, particularly the activity of T cells.

MDSCs are typically found in the tumor microenvironment and are thought to be recruited to the tumor site by various factors, including tumor-derived cytokines and chemokines. Once at the tumor site, MDSCs can suppress the immune response in several ways, including:
-Inhibiting the activation and proliferation of T cells.
-Suppressing the production of cytokines and chemokines that are necessary for an effective immune response.
-Inducing the production of anti-inflammatory cytokines that promote tumor growth and survival.
-Inhibiting the activity of natural killer (NK) cells and other immune cells that are important for tumor surveillance.
Scientific Papers found: Click to Expand⟱
428- Chit,  docx,  CUR,    Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer
- vitro+vivo, Lung, H460 - vitro+vivo, Lung, H1299 - vitro+vivo, Lung, A549 - vitro+vivo, Lung, PC9
MDSCs↓,
TregCell↓,
IL10↓,
NK cell↑,

465- CUR,    Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues
- vitro+vivo, Liver, HepG2 - vitro+vivo, Liver, HUH7 - vitro+vivo, Liver, MHCC-97H
TumCG↓,
MDSCs↓,
TLR4↓,
NF-kB↓,
IL6↓,
IL1↓, IL-1β
PGE2↓,
COX2↓,
GM-CSF↓,
angioG↓,
VEGF↓,
CD31↓,
GM-CSF↓,
α-SMA↓,
p‑IKKα↓, p-IKKα, p-IKKβ
MyD88↓,

3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, Silymarin, a milk thistle extract, has anti-inflammatory, immunomodulatory, anti-lipid peroxidative, anti-fibrotic, anti-oxidative, and anti-proliferative properties.
lipid-P↓,
TumMeta↓, Silymarin exhibits not only anti-cancer functions through modulating various hallmarks of cancer, including cell cycle, metastasis, angiogenesis, apoptosis, and autophagy, by targeting a plethora of molecules
angioG↓,
chemoP↑, but also plays protective roles against chemotherapy-induced toxicity, such as nephrotoxicity,
EMT↓, Figure 2, Metastasis
HDAC↓,
HATs↑,
MMPs↓,
uPA↓,
PI3K↓,
Akt↓,
VEGF↓, Angiogenesis
CD31↓,
Hif1a↓,
VEGFR2↓,
Raf↓,
MEK↓,
ERK↓,
BIM↓, apoptosis
BAX↑,
Bcl-2↓,
Bcl-xL↓,
Casp↑,
MAPK↓,
P53↑,
LC3II↑, Autophagy
mTOR↓,
YAP/TEAD↓,
*BioAv↓, Additionally, the oral bioavailability of silymarin in rats is only 0.73 %
MMP↓, silymarin treatment reduced mitochondrial transmembrane potential, leading to an increase in cytosolic cytochrome c (Cyt c), downregulating proliferation-associated proteins (PCNA, c-Myc, cyclin D1, and β-catenin)
Cyt‑c↑,
PCNA↓,
cMyc↓,
cycD1/CCND1↓,
β-catenin/ZEB1↓,
survivin↓, and anti-apoptotic proteins (survivin and Bcl-2), and upregulating pro-apoptotic proteins (caspase-3, Bax, APAF-1, and p53)
APAF1↑,
Casp3↑,
MDSCs↓, ↓MDSCs, ↓IL-10, ↑IL-2 and IFN-γ
IL10↓,
IL2↑,
IFN-γ↑,
hepatoP↑, Moreover, in a randomized clinical trial, silymarin attenuated hepatoxicity in non-metastatic breast cancer patients undergoing a doxorubicin/cyclophosphamide-paclitaxel regimen
cardioP↑, For example, Rašković et al. studied the hepatoprotective and cardioprotective effects of silymarin (60 mg/kg orally) in rats following DOX
GSH↑, silymarin could protect the kidney and heart from ADR toxicity by protecting against glutathione (GSH) depletion and inhibiting lipid peroxidation
neuroP↑, silymarin attenuated the neurotoxicity of docetaxel by reducing apoptosis, inflammation, and oxidative stress


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   lipid-P↓, 1,  

Mitochondria & Bioenergetics ⓘ

MEK↓, 1,   MMP↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 1,   APAF1↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,   MAPK↓, 1,   survivin↓, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   ERK↓, 1,   HDAC↓, 1,   mTOR↓, 1,   PI3K↓, 1,   TumCG↓, 1,  

Migration ⓘ

CD31↓, 2,   MMPs↓, 1,   TregCell↓, 1,   TumMeta↓, 1,   uPA↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   Hif1a↓, 1,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   GM-CSF↓, 2,   IFN-γ↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 2,   IL2↑, 1,   IL6↓, 1,   Inflam↓, 1,   MDSCs↓, 3,   MyD88↓, 1,   NF-kB↓, 1,   NK cell↑, 1,   PGE2↓, 1,   TLR4↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,  
Total Targets: 60

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: MDSCs, Myeloid-derived suppressor cells
2 Curcumin
1 chitosan
1 Docetaxel
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:672  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page